ID   8505C
AC   CVCL_1054
SY   8505c
DR   BTO; BTO_0005550
DR   CLO; CLO_0001513
DR   CLO; CLO_0050951
DR   EFO; EFO_0022669
DR   CLDB; cl135
DR   CLDB; cl136
DR   AddexBio; C0025002/19
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BCRJ; 0398
DR   BioSample; SAMN01821611
DR   BioSample; SAMN03470935
DR   BioSample; SAMN03472518
DR   BioSample; SAMN03473379
DR   BioSample; SAMN10988556
DR   cancercelllines; CVCL_1054
DR   Cell_Model_Passport; SIDM00996
DR   CGH-DB; 54-1
DR   ChEMBL-Cells; CHEMBL3308353
DR   ChEMBL-Targets; CHEMBL1075387
DR   Cosmic; 889489
DR   Cosmic; 891256
DR   Cosmic; 922365
DR   Cosmic; 924102
DR   Cosmic; 1084283
DR   Cosmic; 1132598
DR   Cosmic; 1152114
DR   Cosmic; 1162837
DR   Cosmic; 1239959
DR   Cosmic; 2036694
DR   Cosmic; 2054105
DR   Cosmic; 2613248
DR   Cosmic-CLP; 924102
DR   DepMap; ACH-001307
DR   DSMZ; ACC-219
DR   DSMZCellDive; ACC-219
DR   ECACC; 94090184
DR   EGA; EGAS00001000978
DR   FANTOM5_SSTAR; 10437-106E5
DR   GDSC; 924102
DR   GEO; GSM886847
DR   GEO; GSM887911
DR   GEO; GSM1669574
DR   IARC_TP53; 1305
DR   JCRB; JCRB0826
DR   LiGeA; CCLE_065
DR   LINCS_LDP; LCL-1686
DR   PharmacoDB; 8505C_31_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1054
DR   PubChem_Cell_line; CVCL_1054
DR   RCB; RCB2103
DR   TKG; TKG 0439
DR   Wikidata; Q54605341
RX   PubMed=1516062;
RX   PubMed=9247707;
RX   PubMed=9290701;
RX   PubMed=14522906;
RX   PubMed=15613457;
RX   PubMed=16924234;
RX   PubMed=17725429;
RX   PubMed=17804723;
RX   PubMed=18713817;
RX   PubMed=19087340;
RX   PubMed=20164919;
RX   PubMed=21566963;
RX   PubMed=21868764;
RX   PubMed=22460905;
RX   PubMed=23162534;
RX   PubMed=23833040;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30737244;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31395879;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   Provider; Altogen; Xenograft model; https://altogenlabs.com/xenograft-models/other-bladder-cervical/8505c-xenograft-model/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Japanese.
CC   Doubling time: 36 hours (PubMed=21566963); ~30-40 hours (DSMZ=ACC-219); ~1.5 days (Note=Lot 11252003) (JCRB=JCRB0826).
CC   HLA typing: A*02:01,26:01; B*39:01,51:01; C*07:02,15:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=23833040; PubMed=30737244; Cosmic-CLP=924102; DepMap=ACH-001307).
CC   Sequence variation: Mutation; HGNC; HGNC:7773; NF2; Simple; p.Glu129Ter (c.385G>T); Zygosity=Homozygous (PubMed=30737244; Cosmic-CLP=924102; DepMap=ACH-001307).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gly (c.742C>G); ClinVar=VCV000376652; Zygosity=Hemizygous (PubMed=1516062; PubMed=14522906; PubMed=21566963; PubMed=23162534; PubMed=30737244; Cosmic-CLP=924102; DepMap=ACH-001307).
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Proteomics; Quantitative.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
CC   Genome ancestry: African=0.58%; Native American=0%; East Asian, North=84.79%; East Asian, South=11.83%; South Asian=0%; European, North=0%; European, South=2.8% (PubMed=30894373).
CC   Misspelling: 8509C; Cosmic=1132598.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): Cosmic-CLP=924102; DSMZ=ACC-219; ECACC=94090184; JCRB=JCRB0826; PubMed=18713817; PubMed=21868764; PubMed=25877200; PubMed=30737244; RCB=RCB2103; TKG=TKG 0439
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 13
ST   D16S539: 12
ST   D18S51: 16
ST   D19S433: 13,14
ST   D21S11: 28,32.2
ST   D2S1338: 17,24
ST   D3S1358: 16,17
ST   D5S818: 10,11
ST   D7S820: 10
ST   D8S1179: 10,13
ST   FGA: 23
ST   Penta D: 9,10
ST   Penta E: 12,15
ST   TH01: 6 (PubMed=25877200)
ST   TH01: 6,9 (Cosmic-CLP=924102; DSMZ=ACC-219; ECACC=94090184; JCRB=JCRB0826; PubMed=21868764; PubMed=30737244; RCB=RCB2103; TKG=TKG 0439)
ST   TPOX: 10,11 (Cosmic-CLP=924102; DSMZ=ACC-219; PubMed=30737244; RCB=RCB2103; TKG=TKG 0439)
ST   TPOX: 11 (ECACC=94090184; JCRB=JCRB0826; PubMed=21868764; PubMed=25877200)
ST   vWA: 17,19
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   78Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 49
//
RX   PubMed=1516062;
RA   Yoshimoto K., Iwahana H., Fukuda A., Sano T., Saito S., Itakura M.;
RT   "Role of p53 mutations in endocrine tumorigenesis: mutation detection
RT   by polymerase chain reaction-single strand conformation
RT   polymorphism.";
RL   Cancer Res. 52:5061-5064(1992).
//
RX   PubMed=9247707; DOI=10.1080/15216549700202901;
RA   Hatakeyama S., Gao Y.-H., Ohara-Nemoto Y., Kataoka H., Satoh M.;
RT   "Expression of bone morphogenetic proteins of human neoplastic
RT   epithelial cells.";
RL   Biochem. Mol. Biol. Int. 42:497-505(1997).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=14522906;
RA   Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R.,
RA   Vigneri P.;
RT   "p73 tumor-suppressor activity is impaired in human thyroid cancer.";
RL   Cancer Res. 63:5829-5837(2003).
//
RX   PubMed=15613457; DOI=10.1677/erc.1.00818;
RA   Onda M., Emi M., Yoshida A., Miyamoto S., Akaishi J., Asaka S.-i.,
RA   Mizutani K., Shimizu K., Nagahama M., Ito K., Tanaka T., Tsunoda T.;
RT   "Comprehensive gene expression profiling of anaplastic thyroid cancers
RT   with cDNA microarray of 25 344 genes.";
RL   Endocr. Relat. Cancer 11:843-854(2004).
//
RX   PubMed=16924234; DOI=10.1038/sj.onc.1209899;
RA   Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.;
RT   "A novel amplification target, DUSP26, promotes anaplastic thyroid
RT   cancer cell growth by inhibiting p38 MAPK activity.";
RL   Oncogene 26:1178-1187(2007).
//
RX   PubMed=17725429; DOI=10.1089/thy.2007.0097;
RA   Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V.,
RA   Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R.,
RA   Trovisco V., Cirnes L., Alves C., Velho S., Soares P.,
RA   Sobrinho-Simoes M.;
RT   "Molecular and genotypic characterization of human thyroid follicular
RT   cell carcinoma-derived cell lines.";
RL   Thyroid 17:707-715(2007).
//
RX   PubMed=17804723; DOI=10.1158/0008-5472.CAN-06-4026;
RA   van Staveren W.C.G., Weiss-Solis D.Y., Delys L., Duprez L., Andry G.,
RA   Franc B., Thomas G., Libert F., Dumont J.-E., Detours V., Maenhaut C.;
RT   "Human thyroid tumor cell lines derived from different tumor types
RT   present a common dedifferentiated phenotype.";
RL   Cancer Res. 67:8113-8120(2007).
//
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. 3rd, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
//
RX   PubMed=19087340; DOI=10.1186/1471-2407-8-371; PMCID=PMC2651892;
RA   Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.;
RT   "Conventional and molecular cytogenetics of human non-medullary
RT   thyroid carcinoma: characterization of eight cell line models and
RT   review of the literature on clinical samples.";
RL   BMC Cancer 8:371.1-371.11(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21566963; DOI=10.3892/ijo.4.3.583;
RA   Ito T., Seyama T., Hayashi Y., Hayashi T., Dohi K., Mizuno T.,
RA   Iwamoto K.S., Tsuyama N., Nakamura N., Akiyama M.;
RT   "Establishment of 2 human thyroid-carcinoma cell-lines (8305C, 8505C)
RT   bearing p53 gene-mutations.";
RL   Int. J. Oncol. 4:583-586(1994).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690; PMCID=PMC3229662;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23162534; DOI=10.3389/fendo.2012.00133; PMCID=PMC3499787;
RA   Saiselet M., Floor S., Tarabichi M., Dom G., Hebrant A.,
RA   van Staveren W.C.G., Maenhaut C.;
RT   "Thyroid cancer cell lines: an overview.";
RL   Front. Endocrinol. 3:133.1-133.9(2012).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2; PMCID=PMC6687785;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//